MARATTO

article · Journal of Immunoassay and Immunochemistry

Strategic analysis of hepatitis B virus serological profile and the diagnostic utility of HBcrAg across Osun and Plateau State, Nigeria

Abstract

Hepatitis B virus (HBV) infection remains a major concern in Nigeria. Nationally, increasing infection rates continue to pose a significant challenge, which may be due to inadequate diagnosis. Known markers, such as Hepatitis B Surface Antigen (HBsAg) and Hepatitis B e antigen (HBeAg), are good at indicating exposure rates, but generally poor at reflecting active viral replication. The hepatitis B core-related antigen (HBcrAg) may provide a clearer picture of the viral activity and treatment response. We conducted a cross-sectional study involving 450 participants aged 16-65 years from hospitals in Osun and Plateau States. HBsAg screening was performed using rapid diagnostic tests, confirmed by enzyme-linked immunosorbent assay (ELISA), and further evaluated for HBeAg and HBcrAg levels. Correlation analysis was used to test the relationships between these markers. Of the 450 participants screened, 188 (41.7%) were confirmed positive for HBV. HBcrAg was observed in adults aged 17-45 years, suggesting replication activity in symptom-free individuals. Atypical serological profiles, such as HBsAg and HBsAb co-positivity, were also identified. Incorporation of HBcrAg in HBV screening, especially in endemic countries, may be useful in assessing HBV replication stage, reactivation, and staging of chronic infection, especially in resource-limited settings.

Research topics

  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Hepatitis Viruses Studies and Epidemiology

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1080/15321819.2026.2639308

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.